Oncology Institute director sells 95,719 shares

Oncology Institute, Inc. director Mohit Kaushal reported open-market sales of 95,719 shares of Common Stock.

Rhea-AI Filing Summary

Oncology Institute, Inc. director Mohit Kaushal reported open-market sales of 95,719 shares of Common Stock. He sold 57,286 shares on April 14, 2026 at a volume-weighted average price of $3.5017 per share and 38,433 shares on April 16, 2026 at a volume-weighted average price of $3.5005 per share.

These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 16, 2025. Following the reported sales, Kaushal directly holds 172,583 shares of Oncology Institute common stock.

Insider Trade Summary 10b5-1

Net Seller: 95,719 shares

Net Sell 2 txns

Insider Kaushal Mohit

Role Director

Sold 95,719 shs ($335K)

Type	Security	Shares	Price	Value
Sale	Common Stock	38,433	$3.5005	$135K
Sale	Common Stock	57,286	$3.5017	$201K

Holdings After Transaction: Common Stock — 172,583 shares (Direct)

Footnotes (3)

1. F1. Represents shares sold pursuant to a Rule 10b5-1 plan adopted by the reporting person on December 16, 2025.
2. F2. Price of $3.5017 was the volume weighted average selling price of all sales by the reporting person on April 14, 2026 within a one-dollar range. Actual prices ranged from $3.5000 to $3.5300. The reporting person hereby undertakes to provide upon request of the Commission staff full information regarding the number of shares sold at each separate price.
3. F3. Price of $3.5005 was the volume weighted average selling price of all sales by the reporting person on April 16, 2026 within a one-dollar range. Actual prices ranged from $3.5000 to $3.5050. The reporting person hereby undertakes to provide upon request of the Commission staff full information regarding the number of shares sold at each separate price.

Key Figures

Shares sold April 14, 2026: 57,286 shares Shares sold April 16, 2026: 38,433 shares Total shares sold in reported trades: 95,719 shares +3 more

6 metrics

Shares sold April 14, 2026 57,286 shares Open-market sale of Common Stock at $3.5017 volume-weighted average price

Shares sold April 16, 2026 38,433 shares Open-market sale of Common Stock at $3.5005 volume-weighted average price

Total shares sold in reported trades 95,719 shares Aggregate of April 14 and April 16, 2026 open-market sales

Holding after transactions 172,583 shares Director’s direct Common Stock ownership following April 16, 2026 sale

VWAP April 14, 2026 $3.5017 per share Volume weighted average selling price; actual range $3.5000–$3.5300

VWAP April 16, 2026 $3.5005 per share Volume weighted average selling price; actual range $3.5000–$3.5050

Key Terms

Rule 10b5-1 plan, volume weighted average selling price, Common Stock

3 terms

Rule 10b5-1 plan regulatory

"Represents shares sold pursuant to a Rule 10b5-1 plan adopted by the reporting person on December 16, 2025."

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

volume weighted average selling price financial

"Price of $3.5017 was the volume weighted average selling price of all sales by the reporting person on April 14, 2026 within a one-dollar range."

Common Stock financial

"security_title: "Common Stock" in each reported non-derivative transaction."

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider activity did Mohit Kaushal report for Oncology Institute (TOI)?

Mohit Kaushal reported selling 95,719 shares of Oncology Institute Common Stock in open-market transactions. He sold 57,286 shares on April 14, 2026 and 38,433 shares on April 16, 2026, as disclosed in a Form 4 insider trading report filed for the company.

At what prices did Mohit Kaushal sell Oncology Institute (TOI) shares?

The April 14, 2026 sale used a volume-weighted average price of $3.5017 per share, with actual prices ranging from $3.5000 to $3.5300. The April 16, 2026 sale used a volume-weighted average price of $3.5005, with actual prices between $3.5000 and $3.5050.

How many Oncology Institute (TOI) shares does Mohit Kaushal hold after these sales?

After completing the reported sales, Mohit Kaushal directly holds 172,583 shares of Oncology Institute Common Stock. This figure reflects his ownership immediately following the April 16, 2026 transaction, as shown in the Form 4 filing’s post-transaction holdings column for his account.

Were Mohit Kaushal’s Oncology Institute (TOI) share sales under a trading plan?

Yes. The filing states that the shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mohit Kaushal on December 16, 2025. Such plans allow insiders to pre-schedule trades, helping separate routine portfolio management from discretionary, market-timed transactions.

What type of transactions were reported for Oncology Institute (TOI) in this Form 4?

Both transactions were open-market sales of Common Stock, coded as “S” in the Form 4. They are classified as non-derivative transactions, meaning they involved direct share sales rather than option exercises or other derivative conversions, according to the filing’s transaction details.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/16/2026 - 07:27 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kaushal Mohit

(Last) (First) (Middle)

C/O THE ONCOLOGY INSTITUTE

18000 STUDEBAKER RD, SUITE 800

(Street)

CERRITOS CALIFORNIA 90703

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Oncology Institute, Inc. [ TOI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/14/2026		S(1)		57,286	D	$3.5017(2)	211,016	D
Common Stock	04/16/2026		S(1)		38,433	D	$3.5005(3)	172,583	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares sold pursuant to a Rule 10b5-1 plan adopted by the reporting person on December 16, 2025.

2. Price of $3.5017 was the volume weighted average selling price of all sales by the reporting person on April 14, 2026 within a one-dollar range. Actual prices ranged from $3.5000 to $3.5300. The reporting person hereby undertakes to provide upon request of the Commission staff full information regarding the number of shares sold at each separate price.

3. Price of $3.5005 was the volume weighted average selling price of all sales by the reporting person on April 16, 2026 within a one-dollar range. Actual prices ranged from $3.5000 to $3.5050. The reporting person hereby undertakes to provide upon request of the Commission staff full information regarding the number of shares sold at each separate price.

	/s/ Mark Hueppelsheuser, Attorney-in-Fact for Mohit Kaushal	04/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)